Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial

A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.

Start Date01 Dec 2025

Sponsor / Collaborator

McMaster University

NCT06370273

/ RecruitingPhase 3

Thromboprophylaxis in Lower Limb Immobilisation (TiLLI): a Multicentre Study Comprising Two Linked Open Label Phase III Randomised Controlled Trials Evaluating the Effectiveness and Cost Effectiveness of Different Methods of Pharmacological Prophylaxis for Patients With Temporary Lower Limb Immobilisation.

The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.
The main questions it aims to answer are:
* whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care)
* whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots.
Participants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication.
Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.

Start Date12 Nov 2024

Sponsor / Collaborator

Queen Mary University of London

ChiCTR2400082184

/ Not yet recruitingPhase 1IIT

Efficacy and safety of fondaparinux in prevention of deep venous thrombosis after total knee arthroplasty study

Start Date01 Apr 2024

Sponsor / Collaborator-

100 Clinical Results associated with Fondaparinux Sodium

100 Translational Medicine associated with Fondaparinux Sodium

100 Patents (Medical) associated with Fondaparinux Sodium

1,949

Literatures (Medical) associated with Fondaparinux Sodium

01 Mar 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Rational design of heparin antagonist: Guanidine-based mimetics unveil key carbohydrate-carbohydrate interactions

Article

Author: Ravindra Bhoge, Preeti ; Jiménez-Barbero, Jesús ; Mahida, Virendrasinh ; Chandra, Ankita ; Payá-García, María ; Kikkeri, Raghavendra ; Gimeno, Ana

Small-molecule inhibitors targeting heparin (HP)-protein interactions represent a promising strategy for developing therapeutic agents against serious bleeding complications. Herein, we report a rational design and synthesis of a library of eight trisaccharide HP mimetics incorporating positively charged guanidinium residues aimed at disrupting the ionic interactions of HP and modulating HP-mediated biological activities. The introduction of guanidine residue in HP backbone significantly influenced the conformational plasticity of l-idose and l-iduronic acid, shifting the major ⁴C₁-conformation to predominant ²S₀-geometries, akin to the role of high sulfation in native HS. Unlike aminoglycosides, the guanidine-based HP mimetics exhibited no antibacterial activity and demonstrated low cytotoxicity towards both cancerous and normal cell lines. When evaluated as potential antidotes for heparin and fondaparinux-mediated blood coagulation, the highly guanidine-substituted HP mimetics displayed sub-micromolar antagonist potency. NMR studies further confirmed the carbohydrate-carbohydrate interactions between fondaparinux and the HP mimetics, providing a mechanistic basis for the observed activity and introducing a new strategy to block HP-mediated biological functions.

01 Feb 2026·BMJ Case Reports

IVC syndrome in a patient with Factor V Leiden mutation

Article

Author: Levasseur, John ; McCann, Edward ; Patel, Kajal ; Postoll-Downs, Melissa

A woman in her 50s with Factor V Leiden and recent surgery with history of multiple right-sided deep venous thromboses not on anticoagulation due to a prior bleeding complication presented with acute left groin pain and discolouration. Physical exam was concerning for a condition in which a large blood clot blocks the major deep veins of the legs causing painful swelling and a pale appearance. CT imaging revealed a massive occlusive thrombus. Point of care ultrasound was significant for a completely collapsed inferior vena cava. The patient’s presentation progressed, and she subsequently underwent clot removal and was started on Heparin for anticoagulation. She was subtherapeutic on heparin and was started on argatroban. On discharge, she was transitioned to fondaparinux.

01 Feb 2026·BMJ Case Reports

Autoimmune heparin-induced thrombocytopenia following cardiac surgery

Article

Author: St Bernard, Rosanne ; Warkentin, Theodore Earl ; Nazy, Ishac

An elderly man underwent cardiac surgery with heparin anticoagulation; postoperatively, the platelet counts steadily fell, reaching 50×10 9 /L on postoperative day 5 (POD5), prompting testing for heparin-induced thrombocytopenia (HIT) antibodies; brain imaging showed parietal stroke. Screening immunoassay for HIT antibodies yielded a strong-positive result; the platelet activation test (serotonin-release assay) gave an atypical profile (strong serotonin release at 0, 0.1 and 0.3 U/mL heparin with only partial inhibition by a platelet Fc receptor-blocking monoclonal antibody). Anticoagulation was changed to argatroban plus high-dose intravenous immunoglobulin. Persisting hypercoagulability prompted a switch to fondaparinux, with gradual platelet count recovery (155×10 9 /L, POD62); neurological abnormalities resolved. Laboratory evaluation confirmed HIT antibodies with heparin-independent platelet-activating properties, indicating autoimmune HIT (aHIT). Besides profound thrombocytopenia (platelet count nadir, 13×10⁹/L), novel aspects of this case of aHIT include early postoperative onset (before POD5) resulting from preoperative heparin exposure and a unique laboratory aHIT antibody profile with partial resistance to Fc receptor blockade.

News (Medical) associated with Fondaparinux Sodium

18 Mar 2025

·www.globenewswire.com

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4’s multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company’s Board of Directors. “We are delighted to welcome Drs. Williams and Stewart to our Board of Directors,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “With their combined expertise spanning critical aspects of R&D and clinical development, we will benefit greatly from their strategic insights as we advance our lead clinical program for urea cycle disorders and our preclinical program for SYNGAP1-related disorders, while continuing to develop additional RNA-targeting medicines designed to upregulate gene expression and meaningfully address diseases where we believe modest increases in protein levels can have a tremendous impact on the lives of patients.” Dr. Williams commented, “CAMP4’s approach is opening exciting possibilities to upregulate gene expression, a long-sought-after and challenging feat in the field of genetic medicine. I look forward to working with the team to unlock the full potential of this approach and ultimately advance novel therapeutics to the clinic.” Dr. Stewart added, “I’m thrilled to join the CAMP4 team and support its mission of advancing programmable RNA therapeutics for genetic diseases where decreased protein expression drives disease pathophysiology. By pioneering new ways to restore gene expression, CAMP4 has the potential to bring life-changing therapies to patients who currently have limited or no disease-modifying treatment options.” With over 30 years in the biopharma industry, Dr. Williams has contributed to the development of several transformative drugs, including LEUKINE®, ENBREL®, ADCETRIS®, TECFIDERA®, APROLIX®, ELOCTATE®, and SPINRAZA®. He was previously President of R&D at Sana Biotechnology and the Founding President & CEO of Codiak BioSciences. Prior to Sana, Dr. Williams served as EVP of R&D at Biogen, and earlier in his career was CEO of ZymoGenetics (acquired by BMS), and held leadership roles at Seattle Genetics, Amgen, and Immunex. Over the course of his career, he has served on the Board of Directors and Advisory Boards of more than two dozen biotech companies. Dr. Stewart currently serves as a Senior Medical Advisor to several biopharma companies, and was most recently the Chief Medical Officer at Rhythm Pharmaceuticals. Prior to this position, he served as Head of R&D at Novelion Therapeutics. Before joining Novelion, he served as corporate Chief Medical Officer at GlaxoSmithKline. With extensive clinical development experience, he has led studies across all stages, from first-in-human trials to large Phase 4 cardiovascular outcome studies. Dr. Stewart has played a key role in the successful registration and launch of multiple therapies, including AVANDIA®, ARIXTRA®, TANZEUM®, and XOLREMDI®. Before transitioning to industry, he served as a Consultant Physician and Head of Clinical Services at the Diabetes Centre in Newcastle upon Tyne, UK, where his research was focused on lipid metabolism and type 2 diabetes. About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of rare and prevalent genetic diseases where increasing healthy protein levels may offer meaningful therapeutic benefits. Our approach allows for targeted gene upregulation by harnessing a fundamental mechanism of how genes are controlled. To increase gene expression, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans, objectives, expectations and intentions. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts Investor Relations:Sandya von der WeidLifeSci Advisorssvonderweid@lifesciadvisors.com Media:Jason Braco, Ph.D.LifeSci Communicationsjbraco@lifescicomms.com

Executive ChangeOligonucleotide

08 Sep 2020

·www.biospace.com

Mylan Acquires Aspen’s European Thrombosis Portfolio for $757.3 Million

The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran. Netherlands-based Mylan is buying the intellectual property and commercialization rights to Aspen Pharmacare ’s thrombosis business in Europe for €641.9 million ($757.25 U.S.). The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran. Under the terms of the deal, Mylan is paying €263.2 million in cash up front, then, using cash from operations, paying €378.7 million on June 25, 2021. The deal is expected to close before December 25, 2021. The portfolio Mylan is buying had a combined net sales for the 12 months ending June 30, 2020, of €231 million. “The acquisition of this thrombosis portfolio is a significant addition to Mylan’s European business that will not only make Mylan the second largest supplier of these products to patients in Europe, according to IQVIA, but also bolster our existing commercial infrastructure to further expand access to complex injectables,” said Rajiv Malik, president of Mylan. “By adding to our highly experienced sales and marketing team, we will further strengthen our current reach in hospitals and enhance the future growth of our biosimilars franchise in Europe.” Aspen will be responsible for manufacture of the drugs and product supply, delivering the finished product to Mylan. Aspen, the companies indicate, has a fully vertically integrated supply chain mostly located in Europe. Aspen Pharmacare is headquartered in Durban, South Africa, and is a global specialty and branded multinational pharma company. Mylan is merging with Pfizer’s generics division Upjohn, to form a new company called Viatris. That merger was announced in July 2019. Upjohn is Pfizer’s off-patent branded and generic established drugs business. It was an all-stock deal, with each Mylan share converted into one share of the new company. Pfizer shareholders will own 57% of the combined new company and Mylan shareholders will own 43%. Mylan has a portfolio across many geographies and therapeutic areas, including central nervous system and anesthesia, infectious disease and cardiovascular, and a robust pipeline, high-quality manufacturing and supply chain. Upjohn’s brands include Lipitor, Celebrex and Viagra, with strong commercial capabilities, including in China and other emerging markets. Viatris is expected to have pro forma 2020 revenues of $19 to $20 billion. It is to be led by Mylan’s current chairman Robert J. Coury, who will act as executive chairman. Michael Goettler, current Group President, Upjohn, will serve as chief executive officer, and Rajiv Malik, current Mylan president, will serve as president. Coury, of today’s announcement, said, “As we continue toward the launch of Viatris, we remain committed to executing on opportunities that will not only add to Mylan’s growth, but that also will be consistent with our vision for Viatris under the Global Healthcare Gateway, which we believe will establish the new company as a true Partner of Choice.” The Global Healthcare Gateway is part of the new branding and vision for Viatris. Viatris is Latin for “three paths,” and those three paths are apparently access, leadership and partnership. In a July 9, 2020 statement, Coury said, “Viatris will be focused on creating a more sustainable healthcare journey for patients worldwide while delivering value to all stakeholders for years to come. The Viatris branding reflects our drive to address the world’s emerging healthcare needs with passion and compassion. It also highlights our goal to chart a new course focused on improving patient outcomes by expanding access to medicine, providing leadership through innovative solutions and building best-in-class partnerships. We also will offer all partners ready access to more markets and the ability to reach more patients around the world through the company’s new and unique Global Healthcare Gateway, which leverages Viatris’ unmatched global infrastructure to connect people around the world to the high quality medicines and services they need, making Viatris a true Partner of Choice.”

AcquisitionExecutive Change

23 Jan 2015

·www.biospace.com

Aspen Pharmacare Ltd. Grabs Rights to Novartis AG’s Mono-Embolex for $142.3 Million

January 23, 2015 By Krystle Vermes , BioSpace.com Breaking News Staff Aspen Pharmacare Holdings announced today that it has acquired the rights to Mono-Embolex from Novartis AG in a deal projected to be worth $142.3 million, according to Reuters . Mono-Embolex is a heparin-based anti-coagulant, sold in the same category as Aspen ’s Arixtra and Fraxiparine. Both of these drugs are meant to reducing the clotting ability of the body. Arixtra is specifically given to patients after undergoing hip, knee or stomach surgery. Blood Clots and Surgery While hip, knee or stomach surgery may provide long-term benefits to patients, there is a constant risk for blood clots associated with these procedures. Medicine such as Arixtra can reduce the chance of developing complications. However, a study funded by the Agency for Healthcare Research and Quality looked at 179 reports between January 1980 and May 2011 to closely examine blood clot risk. DVT, or Deep Vein Thrombus, is the most common type of blood clot that can form after these types of surgery. They can occur in the lower legs or thighs, and slower blood flow (which occurs post-surgery) is often responsible for the development of clots. “As many as four people out of 10 who do not receive medicine to prevent blood clots develop a DVT within 1 or 2 weeks of having major hip or knee surgery,” wrote the authors of the report. “Taking medicine or using a device to prevent blood clots may lower the risk of developing a DVT after hip or knee surgery to 1 or 2 people out of 10.” Medicine and Blood Clot Risk Reduction The main benefit of taking medicine prescribed after surgery is that it eliminates the potential for DVT. There are several medicines that may be administered following a procedure, and they are either given through a shot or a pill. The most common medicines provided to post-surgery patients are Arixtra, Jantoven, Fragmin, Lovenox, Innhep, Coumadin and Xarelto. However, aspirin may also be given, serving as an oral antiplatelet agent. “The main side effect from medicines that prevent blood clots is a small increase in the chance of bleeding,” wrote the authors of the study. “These medicines work by making your blood thinner. Because your blood is thinner, it may not clot as easily when you bleed. Out of 100 people who take medicines to prevent blood clots, up to 8 have problems with bleeding.” BioSpace Temperature Poll What Are Your Predictions for the Price Bidding War? The market has been buzzing about an escalating price war between large payers like Express Scripts and Big Pharma. Multiple deals last week showed Gilead forming exclusive pacts and smaller companies like Kite Pharma starting talks early. What do you think will be the effect on prices? BioSpace wants your opinion! var _polldaddy = [] || _polldaddy; _polldaddy.push( { type: "iframe", auto: "1", domain: "biospace.polldaddy.com/s/", id: "what-are-your-predictions-for-price-bidding-war", placeholder: "pd_1421711966" } ); (function(d,c,j){if(!document.getElementById(j)){var pd=d.createElement(c),s;pd.id=j;pd.src=(' '==document.location.protocol)?' ':' ';s=document.getElementsByTagName(c)[0];s.parentNode.insertBefore(pd,s);}}(document,'script','pd-embed')); Read at BioSpace.com

AcquisitionDrug Approval

100 Deals associated with Fondaparinux Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D01844	Fondaparinux Sodium	B01AX05	DB00569

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angina Pectoris	China	Glaxo Wellcome Production SAS	01 Jan 2008
Myocardial Infarction	China	Glaxo Wellcome Production SAS	01 Jan 2008
Acute Coronary Syndrome	Canada	GSK Plc	22 Mar 2007
Thromboembolism	Australia	Aspen Pharmacare Holdings Ltd.	25 Mar 2002
Angina, Unstable	European Union	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Angina, Unstable	Iceland	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Angina, Unstable	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Angina, Unstable	Norway	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Non-St Elevated Myocardial Infarction	European Union	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Non-St Elevated Myocardial Infarction	Iceland	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Non-St Elevated Myocardial Infarction	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Non-St Elevated Myocardial Infarction	Norway	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Pulmonary Embolism	European Union	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Pulmonary Embolism	Iceland	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Pulmonary Embolism	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
Pulmonary Embolism	Norway	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
ST Elevation Myocardial Infarction	European Union	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
ST Elevation Myocardial Infarction	Iceland	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
ST Elevation Myocardial Infarction	Liechtenstein	Viatris Healthcare (Pty) Ltd.	20 Mar 2002
ST Elevation Myocardial Infarction	Norway	Viatris Healthcare (Pty) Ltd.	20 Mar 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Knee Injuries	Phase 3	France	GSK Plc	01 Dec 2008
Knee Injuries	Phase 3	Germany	GSK Plc	01 Dec 2008
Knee Injuries	Phase 3	Italy	GSK Plc	01 Dec 2008
Knee Injuries	Phase 3	Netherlands	GSK Plc	01 Dec 2008
Knee Injuries	Phase 3	Russia	GSK Plc	01 Dec 2008
Knee Injuries	Phase 3	Spain	GSK Plc	01 Dec 2008
Craniocerebral Trauma	Phase 3	United States	GSK Plc	01 Dec 2007
Fractures, Bone	Phase 3	United States	GSK Plc	01 Dec 2007
Spinal Cord Injuries	Phase 3	United States	GSK Plc	01 Dec 2007
Wounds and Injuries	Phase 3	United States	GSK Plc	01 Dec 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02744092 (CANVAS, CTgov)	Not Applicable	Solid tumor \| Advanced Malignant Solid Neoplasm \| Pulmonary Embolism ... View more	811	rivaroxaban+Edoxaban+Apixaban+Dabigatran (Randomized Arm 1 (DOACs))	yrcofgkpov = rciyerxgkg ngqsaenqlb (zicsabzzjh, frsiaugmro - xezspfdxnq) View more	-	03 Oct 2023
				Warfarin+Fondaparinux+Enoxaparin+Dalteparin (Randomized Arm 2 (LMWH))	yrcofgkpov = yhzsorovax ngqsaenqlb (zicsabzzjh, ktjhkbrkrx - qtxhbbfujh) View more
NCT04406389 (IMPACT, CTgov)	Phase 4	COVID-19	14	Unfractionated heparin+Fondapariniux+Enoxaparin sodium (Intermediate Dose Prophylaxis)	iheeckekie = ahljkzoonf xatsnqseqy (jhwwiaioeo, vyknsolwad - znpcwwfjng) View more	-	21 Sep 2023
				Unfractionated heparin+Fondapariniux+Argatroban+Enoxaparin sodium (Therapeutic Dose Anticoagulation)	iheeckekie = pbhvaqjsme xatsnqseqy (jhwwiaioeo, wilaqssiir - pfwnatsjao) View more
ISTH2023	Not Applicable	Thromboembolism	85	Fondaparinux	wqpconupic(brobdzxynl) = kescboygab xgjfilquaf (ddyfesjdzn ) View more	-	24 Jun 2023
ISTH2023	Not Applicable	Antiphospholipid Syndrome	46	Fondaparinux	obrckpxzde(outoheavrq) = qgsyeublsz ctqnfcuyvm (bhcemccrxz ) View more	-	24 Jun 2023
NCT00789399 (CTgov)	Not Applicable	Coronary Artery Disease \| Venous Thrombosis \| Venous Thromboembolism	78	Fondaparinux (Fondaparinux)	fseprteqyz = ezyufrchlc ioolhsqqpn (dpcydoqfop, esjokvkvfs - tiuonozgag) View more	-	08 Sep 2022
				Placebo (Placebo)	fseprteqyz = cporvequmn ioolhsqqpn (dpcydoqfop, xunifkzbgg - dawawivrul) View more
ESC2022	Not Applicable	COVID-19 \| Critical Illness \| Blood Coagulation Disorders D-dimer	465	D-dimer-driven fondaparinux	lcryjtevok(hvamtdzbul) = skvxpvipgj kdqdiamywq (iohqcmsffu ) View more	Negative	27 Aug 2022
				Standard prophylactic-dose fondaparinux	lcryjtevok(hvamtdzbul) = yqrghcgxcm kdqdiamywq (iohqcmsffu ) View more
NCT01304238 (Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II, Pubmed \| J Am Coll Cardiol)	Not Applicable	Heparin-induced thrombocytopenia	195	Argatroban	wagcdwkgyw(bwxpyqbsuu) = wkeurktecn iopcguvogc (ufmcpnhcbn ) View more	-	28 Nov 2017
				Lepirudin	wagcdwkgyw(bwxpyqbsuu) = atrlyfxmip iopcguvogc (ufmcpnhcbn )
NCT00521885 (BRiEF, CTgov)	Not Applicable	Venous Thrombosis	1	Lovenox 40mg SC Daily	dmjozaiomf(xijiaqpcmm) = apglacacqp qshlccwhgg (gpqyxqibmu, ezqmzcbpuz - hvdkzwjiek) View more	-	01 Nov 2017
NCT00909064 (CTgov)	Phase 4	-	114	Fondaparinux Sodium (Arixtra)	fuwxlufumy(vxiduzkgbz) = hzuxnjmhhv ulvrooxmvp (ogouwqynfy, 2.2) View more	-	15 May 2017
NCT00881088 (PROTECT, Pubmed \| Injury)	Phase 2/3	-	467	Nadroparin	qcaazamfrh(yxxwbjokmc) = elcsfmexwd galiriuklg (gyyyllcwyc, 1.2 - 23.6)	Positive	01 Apr 2017
				Fondaparinux	qcaazamfrh(yxxwbjokmc) = gbjqvbjoec galiriuklg (gyyyllcwyc, 1.4 - 80.7)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Fondaparinux Sodium

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation